C. Malinverni

ORCID: 0009-0003-1120-4439
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Cardiovascular and exercise physiology
  • Cardiovascular Function and Risk Factors
  • Heart Failure Treatment and Management
  • Gastrointestinal Tumor Research and Treatment
  • Bone health and treatments
  • Cardiac Health and Mental Health
  • Viral-associated cancers and disorders
  • Diabetes Treatment and Management
  • Cardiac Imaging and Diagnostics
  • Cardiac Structural Anomalies and Repair

University of Verona
2023-2024

International Mezzo Technologies (United States)
1995

Introduction: Patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) have poor outcome. Time to first relapse progression (POD) has been consistently shown be an independent predictor of survival, patients experiencing early-POD, within 2 years since the diagnosis, representing a subgroup at greater risk death. On contrary, there is paucity large-scale treatment data on beyond (late-POD). Methods: In this international, observational cohort study, we evaluated outcomes amongst...

10.1002/hon.3164_348 article EN Hematological Oncology 2023-06-01
Coming Soon ...